Linezolid Accord (Linezolid)

Linezolid is indicated for several Gram‑positive bacterial infections where conventional therapy may be limited.

• Methicillin‑resistant Staphylococcus aureus (MRSA): effective treatment of skin, soft‑tissue and respiratory infections caused by MRSA.
• Vancomycin‑resistant Enterococcus (VRE): provides an oral option for infections due to VRE.
• Community‑acquired pneumonia: used to treat pneumonia caused by susceptible Gram‑positive organisms.
• Skin and soft‑tissue infections: resolves infections such as cellulitis and abscesses caused by susceptible strains.
• Infections caused by susceptible Gram‑positive bacteria: broad coverage for strains resistant to other antibiotics.

• Linezolid binds to the 23S rRNA of the 50S ribosomal subunit, preventing formation of the initiation complex required for bacterial protein synthesis. By blocking the early stage of translation, it halts bacterial growth without affecting human ribosomes, resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools occurring during therapy.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Thrombocytopenia: significant reduction in platelet count.
• Peripheral neuropathy: nerve damage leading to sensory deficits.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.

When prescribing linezolid, clinicians should consider several safety and handling precautions.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: assess liver enzymes regularly during treatment.
• Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome.
• Myelosuppression: perform complete blood counts to detect thrombocytopenia or anemia.
• Pregnancy category B: use only when potential benefit justifies potential risk.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Linezolid interacts with several drug classes, requiring careful management to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• SSRIs, SNRIs, tricyclic antidepressants: may precipitate serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin toxicity.
• Rifampin: induces metabolism, markedly lowering linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: linezolid may potentiate anticoagulant effect, requiring INR monitoring.
• Erythromycin or clarithromycin: can raise linezolid levels, increasing toxicity risk.
• Carbamazepine and phenytoin: may reduce linezolid exposure, potentially compromising efficacy.